At the news
? MIXEDIMPACT 6/10 PRESS-RELEASE filed Mar 5, 2026 at 07:00 ET
Tango Therapeutics reported financial results for Q4 and full year 2025, highlighted by a strong cash position of $343.1 million, reduced net losses year-over-year, and advancing its vopimetostat clinical program in pancreatic cancer. The company initiated a clinical supply agreement with Erasca and continues enrollment in combination trials with Revolution Medicines, with initial data expected in 2026. Leadership changes include CEO succession and expanded regulatory leadership.
- Cash, cash equivalents, and marketable securities totaled $343.1 million as of December 31, 2025, providing runway into 2028.
- Collaboration revenue dropped to $0 in Q4 2025 from $5.4 million in Q4 2024; full-year 2025 collaboration revenue was $62.4 million vs. $30.0 million in 2024, driven by recognition of deferred revenue from Gilead.
- Net loss narrowed to $101.6 million in 2025 from $130.3 million in 2024; Q4 2025 net loss was $38.7 million vs. $30.8 million in Q4 2024.
- Vopimetostat pivotal study in 2L pancreatic cancer expected to start in 2026; initial combination data with RAS(ON) inhibitors anticipated in 2026.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access